** Shares of vaccine maker Moderna fall 13.6% to $36.20 premarket
** Co cut its 2025 sales forecast by $1 billion, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines
** Co expects $1.5 bln to $2.5 bln in annual revenue, lower than its prior forecast of $2.5 bln to $3.5 bln
** Analysts on average were expecting annual revenue of $2.95 bln, according to data from LSEG
** Co expects to end 2025 with cash and investments of about $6 billion
** Up to last close, stock had fallen 61.4% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。